The University of Manitoba Department of Internal Medicine’s Section of Hepatology is undertaking a five-year study to identify why Nonalcoholic fatty liver disease (NAFLD) is the most prevalent disease in Canada, with the Canadian Liver Foundation estimates 25% of...
Wuxi Hisky Medical Technologies Co Ltd, a Chinese medical device venture, has launched an innovative, non-invasive liver disease detection product. Called iLivTouch, the company uses multichannel imaging-guided transient elastography, a breakthrough in related medical...
HistoIndex and the Institute of Liver & Biliary Sciences (ILBS) in New Delhi, India have jointly launched a Centre of Excellence (CoE) to aid diagnostics and clinical trials focusing on NASH. What is the CoE? The CoE is HistoIndex’s first Genesis Imaging Service...
UPMC McGowan Institute for Regenerative Medicine spearheads the growing of genetically modified miniature human livers to emulate human liver disease progression and support ongoing therapeutics testing. Reporting in the UPMC news, the results were published in a...
Dr. Samuel Klein declares that nonalcoholic fatty liver is an “unrecognized epidemic” among people with type 2 diabetes. Metabolic complications arise with the development of obesity—including NAFLD and its more severe state, nonalcoholic steatohepatitis (NASH),...
High Point Clinical Trials Center, LLC (HPCTC), the largest independent clinical research site in North Carolina, reports it has partnered with ProSciento, a specialized CRO exclusively focused on metabolic diseases, to join as a NASH PASS site partner. ProSciento has...
